← Sage — Cancer · Sage hub

Sage — A Metabolic Hypothesis of Breast Cancer

Insulin Receptor Overexpression, Hyperinsulinemia, Metabolic Nutritional Interventions, and the Two-Step Metabolic Cancer Paradigm

Disclaimer. This essay presents a metabolic hypothesis intended for intellectual exploration and clinical discussion. It is not medical advice, diagnosis, or a treatment protocol. Mechanisms discussed are interpretive except where a specific experimental result is cited. Individual circumstances vary; any interventions should be undertaken only under appropriate medical supervision. Prolonged fasting, fasting-mimicking diets, and ketogenic or very-low-carbohydrate diets carry real risks (electrolyte imbalance, hypoglycemia, sarcopenia risk in frail or cachectic patients, refeeding issues, potential unintended effects on metastatic behavior in some models) and require medical oversight.

We are born with perfect biology.

That is the first and most radical claim of the metabolic philosophy of medicine. Perfect for intermittent fuel availability, natural circadian entrainment, and the obligatory movement-strength hormesis that defined hominin life. What we label disease is, in the overwhelming majority of chronic cases, not a random error or a software bug in the genome. It is the predictable downstream consequence of a biology operating in chronic compensatory mode because its upstream ATP-generating capacity has been chronically compromised by mismatch. Acute compensation is life-saving. Chronic compensation becomes the pathology we name and attempt to suppress.

Breast cancer is no exception.

Conventional Hypothesis versus Metabolic Hypothesis

The dominant paradigm treats breast cancer as a genetic disease. Accumulated somatic mutations in proto-oncogenes and tumor-suppressor genes, amplified by estrogen receptor signaling and family history, drive the hallmarks: sustained proliferation, evasion of apoptosis, genomic instability, and metastatic competence. Targeted agents, endocrine therapy, and genomic profiling have produced real gains for defined subsets. Yet the model remains incomplete. It struggles to explain why metabolic factors such as high insulin are associated with both incidence and outcome.^2,3 In the author’s reading, it also leaves open why penetrance varies even among high-risk carriers, and why residual mortality and acquired resistance persist despite increasingly precise genetic targeting.

The mitochondrial-metabolic hypothesis begins one layer upstream. Cancer originates as a primary cellular energy crisis—mitochondrial inefficiency in fuel utilization and ATP production—creating a dysfunctional milieu that secondarily promotes genomic instability, selects for mutations that stabilize metabolic compensation, and permits the hallmarks to emerge. On this hypothesis, hyperinsulinemia is not a passive correlate. It is both a marker of the upstream mismatch and an active growth signal that selects for the compensatory phenotype.

The Two-Step Metabolic Cancer Paradigm and Crabtree–Warburg Progression

Step one is the initiating bioenergetic insufficiency. Chronic mismatch—perpetual high glucose and insulin, disrupted circadian entrainment, loss of strength hormesis—impairs oxidative phosphorylation. The cell activates a primitive glycolysis rescue, an ancestral fermentation program suited to unstable fuel.

This is the Crabtree effect: in some cells, a glucose- and time-dependent suppression of oxidative phosphorylation accompanied by a compensatory rise in glycolytic flux and substrate-level phosphorylation. Acute Crabtree compensation preserves ATP. On this hypothesis, when the insult becomes chronic, the phenotype locks in as the Warburg effect—persistent aerobic glycolysis, elevated lactate, and a hybrid metabolism that prioritizes carbon-unit acquisition for biomass over efficient ATP yield. In the author’s reading, Crabtree is the reversible, substrate-driven precursor; Warburg is the selected, stable state.

Step two is natural selection within the resulting pleiomorphic population. Subclones optimized for glycolytic flux and growth signaling enjoy a fitness advantage in the hyperinsulinemic, nutrient-variable microenvironment. On this hypothesis, mutations arise secondarily from mitochondrial ROS, replication stress, and failed quality control; they are retained when they stabilize the carbon-efficient, apoptosis-resistant state. The Warburg phenotype, on this reading, is not a byproduct of growth. It may be a rescue program that selection locks in.

Insulin Receptor Data Fit the Paradigm Directly

In 159 breast tumors, insulin receptor content was more than six times higher than in normal breast tissue, and the receptors were functional: they bound insulin and activated tyrosine kinase.¹ Many cancer cells preferentially express the IR-A isoform—the fetal/oncofetal splice variant—which binds IGF-II with high affinity and, when activated by IGF-II, signals mainly for growth rather than metabolism, which may create an autocrine/paracrine loop.¹⁰

The clinical correlates follow. Among 512 women with early-stage breast cancer, those in the highest quartile of fasting insulin had twice the hazard of distant recurrence and 3.1 times the hazard of death of those in the lowest quartile, associations that persisted after adjustment for tumor and treatment variables.² In the Women’s Health Initiative, among postmenopausal women not on hormone therapy, the top quartile of insulin was associated with 2.4 times the breast-cancer risk of the bottom quartile; the obesity association largely attenuated once insulin was accounted for.³

Hyperinsulinemia therefore does double duty: it reflects the chronic mismatch that drives step-one mitochondrial insufficiency and Crabtree compensation, and it supplies the mitogenic ligand that selects for IR-A-overexpressing, glycolytic subclones in step two. The genetic lesions catalogued by precision oncology are real; in the author’s reading, they are downstream stabilizers of an upstream energy crisis.

Metabolic Nutritional Interventions Combined with Conventional Oncology Management

Metabolic nutritional interventions—cyclic prolonged fasting or fasting-mimicking diets (FMD), ketogenic or well-formulated very-low-carbohydrate diets, and related calorie-restricted approaches—aim to lower the insulin-glucose signal, reduce IGF-1, generate ketones as alternative fuels, and create differential stress between normal and malignant cells. In the two-step framework these interventions may temporarily remove the chronic high-insulin/glucose driver of Crabtree rescue and Warburg selection, while normal cells retain greater fuel flexibility and oxidative capacity. They are positioned as time-limited or cyclical adjuncts to chemotherapy, endocrine therapy, or targeted agents, not replacements.

Human data remain limited, heterogeneous, and mostly from small trials or early-stage/mixed populations. In the author’s reading, published reviews of intermittent fasting or dietary interventions during chemotherapy suggest feasibility and safety in non-cachectic patients but find inconsistent effects on clinical toxicities and hard survival endpoints, largely due to small samples, variable protocols, and compliance issues.

Fasting and Fasting-Mimicking Diets

The phase II DIRECT trial (HER2-negative stage II/III breast cancer, n=131) found no overall difference in grade ≥3 toxicity between FMD and regular diet (dexamethasone omitted in the FMD group), yet patients using the FMD more often had a radiological response and, in per-protocol analysis, a Miller-Payne 4/5 pathological response, and reduced chemotherapy-induced DNA damage in T-lymphocytes.⁴ For metastatic disease, a non-randomized subanalysis of NCT03340935 reported median overall survival of 30.3 months versus 17.2 months in 14 advanced TNBC patients receiving first-line carboplatin-gemcitabine plus cyclic FMD versus a retrospective cohort of 76 consecutive patients at the same institute on carboplatin-based chemotherapy alone (log-rank p=0.041; multivariable and propensity-matched HR ≈0.40).⁵ The phase II BREAKFAST trial in early-stage TNBC reported a 56.6% pathologic complete response rate in 30 patients with cyclic 5-day FMD plus anthracycline-taxane neoadjuvant chemotherapy (17 of the 30 also took metformin, a prescription drug; the trial had no chemotherapy-only control arm); early on-treatment downmodulation of intratumoral glycolysis/pyruvate metabolism predicted pathologic complete response.⁶

Mechanistically, normal cells may enter a maintenance mode via reduced IGF-1/insulin signaling (differential stress resistance), while cancer cells with constitutive growth signaling or high IR-A expression may fail to adapt fully and become relatively more sensitive (differential stress sensitization). Acute reduction of glucose availability may pressure the Crabtree-to-Warburg phenotype, and immune shifts (reduced immunosuppressive myeloid cells, increased activated CD8+ T cells) may contribute.

Ketogenic and Very-Low-Carbohydrate Diets

The Keto-CARE trial (NCT03535701) was a single-arm feasibility study of a personalized well-formulated ketogenic diet in 20 women with stage IV metastatic breast cancer undergoing chemotherapy. Participants achieved sustained nutritional ketosis (mean capillary β-hydroxybutyrate 0.8 mM in the supervised phase, 0.7 mM later), lost ~10% body weight (primarily fat), and showed significant reductions in fasting glucose, insulin, and insulin resistance that persisted at six months, with acceptable safety.⁷

Randomized trials by Khodabakhshi and colleagues provide additional signals. An MCT-based ketogenic diet versus standard diet for three months in patients with locally advanced or metastatic breast cancer on chemotherapy reduced fasting blood sugar, body weight, and fat mass, with higher overall survival in the neoadjuvant subgroup (p=0.04) and no severe adverse effects on lipids or organ markers.⁸ A separate 12-week RCT in locally advanced and metastatic patients found lower adjusted insulin and TNF-α, higher IL-10, reduced tumor size, and significant downstaging in locally advanced disease on the ketogenic arm; no significant difference in response rate was observed in the metastatic subgroup.⁹

Preclinical work in mice has shown that a ketogenic diet can suppress primary breast-tumor growth while also enhancing metastatic potential via BACH1-mediated transcriptional programs.¹¹ This dual signal underscores the need for careful monitoring and larger controlled trials.

Principle-Based Framing

Under the metabolic philosophy, these interventions may act upstream of genetic hallmarks by lowering the selective pressure for IR-A-high, glycolytic clones (step two) and by intermittently reversing the substrate conditions that sustain Crabtree compensation (step one). Normal cells can oxidize ketones and fatty acids efficiently; on this hypothesis, many tumor cells, locked into hybrid Warburg metabolism and high insulin/IGF dependence, cannot. The net effect predicted is improved therapeutic index of conventional agents—greater tumor vulnerability with relative protection of normal tissues—provided compliance is high and sarcopenia is avoided. Broader nutritional counseling during chemotherapy may offer preliminary benefits for weight management, fatigue, and treatment tolerance, but hard oncologic endpoints remain underpowered.

EnSurf Relevance

EnSurf operationalizes the metabolic philosophy through three pillars that restore ancestral ATP-generating capacity and lower the insulin signal that selects for the cancer phenotype.

Fuel—animal fats and proteins, microbiota-accessible carbohydrates, ketones, intermittent fasting, cyclic fasting-mimicking periods, and well-formulated ketogenic or very-low-carbohydrate approaches—may reduce fasting insulin and glucose while supplying substrates mitochondria oxidize cleanly. Circadian entrainment by natural light and sleep timing may realign mitochondrial quality control and redox balance, reducing the chronic compensatory drive. Strength—resistance training plus targeted mitochondrial stacks—may increase mitochondrial density and quality, raising the ATP ceiling so that Crabtree rescue is less necessary.

The same interventions that reverse insulin resistance in metabolic disease are predicted, under this framework, to reduce the selective pressure that favors IR-A-high, Warburg-adapted breast-cancer clones and to improve the therapeutic index of conventional oncology management when applied as a time-limited or cyclical adjunct around treatment cycles.

Anyone in cancer treatment should try fasting, a fasting-mimicking diet, or a ketogenic diet only with their oncology team. Talk with your physician before changing how you eat during treatment.

Conclusion

Breast cancer, like other chronic diseases under the metabolic philosophy of medicine, may be best understood as chronic compensatory mode in a biology tuned for ancestral entrainment. The two-step paradigm—initiating mitochondrial ATP deficit progressing through Crabtree to selected Warburg metabolism—places the elevated insulin receptors, the strong clinical associations with fasting insulin, and the preliminary signals from metabolic nutritional interventions (cyclic fasting/FMD and ketogenic diets) in coherent upstream context. Mutations and estrogen signaling remain important, but on this hypothesis they are midstream and downstream phenomena. Restoring mitochondrial capacity and periodically lowering the insulin signal through Fuel, Circadian, and Strength is not an alternative to conventional care; it is a possible upstream lever that may make the rest more coherent. Current evidence is promising yet preliminary: feasibility and metabolic improvements are consistent, toxicity reduction and survival signals are heterogeneous and often limited by compliance and sample size, and potential risks (including metastatic behavior in some preclinical models) require further study. Larger randomized trials are required before any change in standard practice. In the interim, the data support continued mechanistic exploration of how restoring periods of ancestral fuel scarcity and insulin sensitivity can improve the therapeutic index of conventional oncology management.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 31, 2026.

References

1. Papa V, Pezzino V, Costantino A, et al., 1990. Elevated insulin receptor content in human breast cancer. Journal of Clinical Investigation 86(5):1503-1510. doi:10.1172/JCI114868
2. Goodwin PJ, Ennis M, Pritchard KI, et al., 2002. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. Journal of Clinical Oncology 20(1):42-51. doi:10.1200/JCO.2002.20.1.42
3. Gunter MJ, Hoover DR, Yu H, et al., 2009. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute 101(1):48-60. doi:10.1093/jnci/djn415
4. de Groot S, Lugtenberg RT, Cohen D, et al., 2020. Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nature Communications 11(1):3083. doi:10.1038/s41467-020-16138-3
5. Ligorio F, Lobefaro R, Fucà G, et al., 2024. Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: a subanalysis of the NCT03340935 trial. International Journal of Cancer 154(1):114-123. doi:10.1002/ijc.34701
6. Ligorio F, Vingiani A, Torelli T, et al., 2025. Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients. Cell Metabolism 37(2):330-344.e7. doi:10.1016/j.cmet.2024.11.004
7. Buga A, Harper DG, Sapper TN, et al., 2024. Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: the Keto-CARE trial. PLoS One 19(1):e0296523. doi:10.1371/journal.pone.0296523
8. Khodabakhshi A, Akbari ME, Mirzaei HR, et al., 2020. Feasibility, safety, and beneficial effects of MCT-based ketogenic diet for breast cancer treatment: a randomized controlled trial study. Nutrition and Cancer 72(4):627-634. doi:10.1080/01635581.2019.1650942
9. Khodabakhshi A, Akbari ME, Mirzaei HR, et al., 2021. Effects of ketogenic metabolic therapy on patients with breast cancer: a randomized controlled clinical trial. Clinical Nutrition 40(3):751-758. doi:10.1016/j.clnu.2020.06.028
10. Frasca F, Pandini G, Scalia P, et al., 1999. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Molecular and Cellular Biology 19(5):3278-3288. doi:10.1128/MCB.19.5.3278
11. Su Z, Liu Y, Xia Z, et al., 2024. An unexpected role for the ketogenic diet in triggering tumor metastasis by modulating BACH1-mediated transcription. Science Advances 10(23):eadm9481. doi:10.1126/sciadv.adm9481

Related: Sage — Cancer · Sage — Warburg and Crabtree · Sage — Diabetes · Sage — Fuel · Sage — Brown Fat · Sage — Hepatology · Sage — mRNA Vaccine-Associated Cancer Relapse.

See the notice at the top of this page. Working hypothesis, not medical advice.